89 studies found for:    PNP
Show Display Options
Rank Status Study
1 Not yet recruiting BlueWind Medical Reprieve System for the Treatment of PNP
Condition: Peripheral Neuropathy
Intervention: Device: The Reprieve System
2 Completed Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Conditions: Head and Neck Cancer;   Advanced Solid Tumors
Intervention: Genetic: Ad/PNP and fludarabine monophosphate
3 Unknown  A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: Docetaxel-PNP
4 Recruiting Arterial and Plethysmographic Waveforms Variables as Predictors of Hemodynamic Response to Pneumoperitoneum
Conditions: Pneumoperitoneum;   Heart Output Disorder
Intervention: Procedure: Pneumoperitoneum
5 Unknown  N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Mesothelioma
Interventions: Drug: N-Acetylcysteine;   Drug: Placebo
6 Unknown  The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Placebo;   Drug: Pancreatic Polypeptide (PP)
7 Completed Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)
Condition: Systemic Mycotic Infection
Interventions: Drug: SYP-1018 200mg;   Drug: Voriconazole 200mg
8 Completed Effect of Alcohol on Cephalic Phase Reflex and Gene Expression
Conditions: Type 2 Diabetes;   Inflammation;   Carbohydrate&Lipid Metabolism;   Oral Processing
Interventions: Dietary Supplement: alcohol;   Dietary Supplement: Placebo
9 Completed A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment
Conditions: Postherpetic Neuralgia (PHN);   Peripheral Nerve Injury (PNI);   Non-diabetic Painful Peripheral Polyneuropathy
Interventions: Drug: Qutenza;   Drug: Pregabalin
10 Completed Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch
Conditions: Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN);   or Peripheral Nerve Injury (PNI)
Interventions: Drug: QUTENZA;   Drug: Lidocaine;   Drug: Tramadol
11 Recruiting The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion
Condition: Pre-diabetes
Interventions: Drug: Control;   Drug: Xenin-25 without atropine;   Drug: GIP without atropine;   Drug: Placebo with atropine;   Drug: Xenin-25 with atropine;   Drug: GIP with atropine;   Drug: GIP plus Xenin-25 without atropine;   Drug: GIP plus Xenin-25 with atropine
12 Completed A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects
Condition: Obesity
Interventions: Drug: PP 1420;   Drug: Placebo
13 Unknown  Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy
Condition: Diabetic Neuropathies
Intervention: Procedure: Intraarterial bone marrow progenitor cell transplantation
14 Unknown  A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine
15 Terminated
Has Results
Metabolic Factors of Outcomes From Gastric Bypass Surgery
Condition: Obesity
Intervention:
16 Unknown  Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool
Condition: Substance Withdrawal Syndrome
Intervention:
17 Active, not recruiting Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Neuroendocrine Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: sorafenib tosylate
18 Recruiting Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed By Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Biological: ziv-aflibercept;   Radiation: computed tomography perfusion imaging;   Other: laboratory biomarker analysis
19 Suspended Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
20 Recruiting Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Liver Metastases;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: everolimus;   Other: placebo;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years